Comparing high-resolution and pQCT scans to view bone and muscle structure
Comparison of Bone Microarchitecture Analysed by High Resolution Peripheral Microscanner (HR-pQCT) and Peripheral Microscanner (pQCT) in Pathologies With Bone Loss and/or Muscle Loss
NA · Centre Hospitalier Universitaire de Saint Etienne · NCT06541548
This study will try high-resolution CT (HR-pQCT), pQCT, and DXA scans to see if they reveal bone and muscle microarchitecture changes in adults at risk of osteoporosis or muscle loss.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne (other) |
| Locations | 1 site (Saint-Etienne) |
| Trial ID | NCT06541548 on ClinicalTrials.gov |
What this trial studies
Participants with osteoporosis risk or related conditions (for example rheumatoid arthritis, spondyloarthritis, chronic kidney disease, endocrinopathies, sarcopenia, obesity, anorexia, constitutional thinness, or Parkinson's disease) and a control group will undergo imaging with HR-pQCT (XtremeCT), pQCT (XCT 3000) and DXA. The study compares cortical porosity, trabecular volume and other microarchitectural measures between pathological groups and age-matched controls to distinguish disease-related changes from normal aging. Imaging data will be collected at a single center (CHU Saint-Etienne) and analyzed to characterize differences across conditions. Results aim to clarify which imaging modality best detects microstructural changes that relate to bone fragility.
Who should consider this trial
Good fit: Ideal candidates are adults treated at CHU Saint-Etienne with osteoporosis risk or bone fragility and associated conditions listed in the protocol (inflammatory joint disease, chronic kidney disease, specified endocrinopathies, sarcopenia, obesity, anorexia, constitutional thinness, or Parkinson's disease) as well as eligible control participants with recent acute spinal/radicular pain meeting the control criteria.
Not a fit: Patients who do not consent, who are taking long-term medications known to induce bone loss (where exclusions apply), or who cannot undergo the imaging procedures are unlikely to receive benefit from participation.
Why it matters
Potential benefit: If successful, the study could improve identification of patients at higher fracture risk and guide more targeted prevention or treatment.
How similar studies have performed: Previous research has shown HR-pQCT can reveal microarchitectural bone changes that DXA misses, but head-to-head comparisons across the wide set of pathologies included here remain relatively limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: For the patients: Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies: * Osteoporosis defined by: History of a documented brittle bone fracture * Bone fragility: Patient with indication for bone densitometry but no history of fracture * Inflammatory joint disease: * Rheumatoid arthritis * Spondyloarthritis * Chronic kidney disease * Endocrinopathies: * Primary hyperparathyroidism * Constitutional thinness * Anorexia nervosa * Obesity (BMI \>30) * Sarcopenia * Neuropathies - Parkinson's disease For the controls: Acute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent Exclusion Criteria: * No sign written consent For the controls: * Medications inducing bone loss: * anti-aromasin or GnRH agonist for at least 6 months, * corticosteroids (dose ≥ 5 mg/d for 6 months) * anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months) * History of fracture due to bone fragility * Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)
Where this trial is running
Saint-Etienne
- Chu Saint Etienne — Saint-Etienne, France (RECRUITING)
Study contacts
- Principal investigator: Hubert MAROTTE, PhD — Centre Hospitalier Universitaire de Saint Etienne
- Study coordinator: Hubert MAROTTE, PhD
- Email: hubert.marotte@chu-st-etienne.fr
- Phone: (0)477127643
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Osteoporosis Risk, Bone Loss, Bone microarchitecture, Bone fragility, osteoporosis